Rifaximin n Irritable Bowel Syndrome.docVIP

Rifaximin in Irritable Bowel Syndrome Rationale, Evidence and Clinical Use Mohammed Saadi, MD, Richard W. McCallum, MD, FACP, FRACP, FACG Ther Adv Chronic Dis.?2013;4(2):71-75.? Abstract and Introduction Abstract Irritable bowel syndrome (IBS) is the most common functional bowel disease that affects up to 15% of the US population. The majority of patients with IBS have significant bloating and gas. Recent evidence is beginning to suggest that patients with IBS may have an alteration in the gastrointestinal flora. Specifically, findings suggest that patients with IBS have excessive bacteria in